STEPS

New Drug Reviews

Reslizumab (Cinqair) for Eosinophilic Asthma

 

Am Fam Physician. 2017 Nov 15;96(10):671-672.

Reslizumab (Cinqair) is a monoclonal antibody labeled for adjunctive therapy in patients with severe eosinophilic asthma.1 It antagonizes interleukin-5, blocking the formation and activity of eosinophils to reduce inflammation and remodeling.2

 Enlarge     Print

DrugDosageDose formCost*

Reslizumab (Cinqair)

3 mg per kg

10-mg/1-mL vial of intravenous solution

$905


*—Estimated retail price of one month's treatment based on information obtained at http://www.drugs.com (accessed October 12, 2017). Price listed does not include cost of administration by a health care professional.

DrugDosageDose formCost*

Reslizumab (Cinqair)

3 mg per kg

10-mg/1-mL vial of intravenous solution

$905


*—Estimated retail price of one month's treatment based on information obtained at http://www.drugs.com (accessed October 12, 2017). Price listed does not include cost of administration by a health care professional.

SAFETY

Anaphylactic reactions have been reported in up to 0.3% of patients.1 Reslizumab should be administered in a health care setting, and patients should be monitored after administration for signs of hypersensitivity or anaphylaxis.1 If asthma worsens in severity or becomes uncontrolled after infusion of reslizumab, therapy should be reassessed and patients should seek further medical treatment.1 Because use of reslizumab may increase the risk of asthma exacerbation in children and adolescents, it should not be used in this age group. It should also not be used to treat acute asthma exacerbations in patients who have deteriorating disease.

In clinical trials, malignant neoplasm was more common in patients receiving reslizumab (0.6%) compared with placebo (0.3%). The malignancies were diverse in nature and were diagnosed within six months of exposure.1

Reslizumab may diminish the immune response against parasitic infections. Patients should be treated for parasitic infections before initiating reslizumab. If a patient develops a parasitic infection while taking reslizumab and does not respond to antiparasitic treatment, reslizumab should be discontinued.1 Reslizumab has not been studied in pregnant or breastfeeding women.

TOLERABILITY

Reslizumab is generally well tolerated, although oropharyngeal pain has been reported.13 Musculoskeletal pain may also occur on the day of infusion,

Address correspondence to Anna Bondar, PharmD, BCPS, at annabonrad@gmail.com. Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations.

REFERENCES

1. DailyMed. Drug label information. Cinqair—reslizumab injection, solution, concentrate. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=053b9158-2a5b-48b9-bf47-5fa78a35ec33. Accessed May 5, 2017.

2. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicenter, parallel, double-blind, randomized, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366.

3. Castro M, Mathur S, Hargreave F, et al.; Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–1132.

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, MMedEd, Contributing Editor.

A collection of STEPS published in AFP is available at https://www.aafp.org/afp/steps.

 

 

Copyright © 2017 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

CME Quiz

More in AFP


Editor's Collections


Related Content


MOST RECENT ISSUE


Dec 15, 2017

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article